Drug intelligence / Profile preview

YHC1102

Development stage: Preclinical
Lead developer: Yuhan
Administration: Oral

Overview

YHC1102 is an investigational drug candidate currently in preclinical development by Yuhan Corporation for the treatment of chronic kidney disease (CKD). As an early-stage pipeline asset, specific pharmacological details, including its chemical structure, molecular target, and specific mechanism of action, have not been publicly disclosed in corporate filings or clinical databases. The development of YHC1102 represents Yuhan's strategic research and development efforts to address unmet medical needs in renal health and metabolic diseases.

Beyond the preview

Go deeper on YHC1102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHC1102.

Explore the full profile